London, United Kingdom
Multiomic Health, founded in 2021 in the United Kingdom, is at the forefront of precision medicine for Cardiovascular Renal Metabolic (CRM) diseases. With a slogan of "AI-Enabled Precision Medicine for Cardiovascular Renal Metabolic (CRM) Disease," the company embodies innovation in the intersection of AI, Biotechnology, Health Care, Health and Wellness, and Life Sciences.
Utilizing a patient-focused approach, Multiomic Health integrates AI-driven analytics with curated patient-derived datasets, allowing for nuanced identification and targeting of biomarkers specific to patient subpopulations. This strategic method results in the development of therapeutic candidates that are tailor-made for distinct patient endotypes, marking a significant advancement in precision therapeutics.
The company recently secured a $6.20M Seed Round investment on 04 May 2023, backed by prominent investors such as MMC Ventures, Ada Ventures, Hoxton Ventures, Verve Ventures, and Selvedge Venture. This funding highlights strong confidence in Multiomic Health's innovative capabilities and potential for impact in precision healthcare.
